Lung Cancer Trial, Not Yet Recruiting NCT07661251 Sponsor: Laura Longshaw Condition: Lung Cancer
Back to Lung Cancer

Lung Cancer Trial, Not Yet Recruiting

NCT07661251
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with non-small cell lung cancer (a specific type of lung cancer) at an advanced stage (stage 3B or stage 4), and who are receiving one of the immunotherapy drugs pembrolizumab, atezolizumab, or nivolumab (with or without chemotherapy) as part of their treatment — whether before surgery, after surgery, or to manage the disease long-term — at Ysbyty Gwynedd hospital.
  • People whose general health and ability to carry out daily activities meets a certain minimum level, as measured by a standard medical scale (a score of less than 2 on the WHO performance status scale) (confirm with trial site).
  • People who are able to make their own informed decisions about participating.
  • People who do not have other health conditions that are currently uncontrolled or poorly managed.
  • People who are able to wear a biosensor bracelet (a wearable health-monitoring device).
  • People who are able to understand English.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose general health and ability to carry out daily activities falls below a certain level on a standard medical scale (a score of more than 2 on the WHO performance status scale) (confirm with trial site).
  • People who have other health conditions that are currently uncontrolled or poorly managed.
  • People who are not able to make their own informed decisions about participating.
  • People who are unable to wear the biosensor bracelet.
  • People who have complete hair loss (no hair remaining on the head).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Laura Longshaw
Registry
ClinicalTrials.gov
Start date
15 June 2026
Est. completion
1 April 2028

Primary endpoints

Is TimeTeller able to identify the molecular clock phase in patients with advanced NSCLC from analysis of hair samples/buccal mucosa in at least 75% of the participants?

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov